Lifesci Capital Issues Optimistic Estimate for CNTA Earnings

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Analysts at Lifesci Capital lifted their FY2025 earnings per share estimates for Centessa Pharmaceuticals in a research report issued to clients and investors on Thursday, November 13th. Lifesci Capital analyst F. Brisebois now expects that the company will earn ($1.37) per share for the year, up from their prior estimate of ($1.39). Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for Centessa Pharmaceuticals’ Q4 2025 earnings at ($0.39) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS and FY2026 earnings at ($1.61) EPS.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02).

CNTA has been the topic of a number of other reports. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, November 5th. Stephens assumed coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They set an “overweight” rating and a $35.00 target price on the stock. Finally, Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.11.

Centessa Pharmaceuticals Stock Performance

CNTA stock opened at $27.32 on Monday. Centessa Pharmaceuticals has a twelve month low of $9.60 and a twelve month high of $29.29. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of -14.93 and a beta of 1.56. The business’s fifty day simple moving average is $23.36 and its two-hundred day simple moving average is $17.65. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36.

Insider Activity

In other news, insider Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $21.40, for a total value of $174,880.80. Following the transaction, the insider directly owned 197,394 shares in the company, valued at approximately $4,224,231.60. This trade represents a 3.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Iqbal J. Hussain sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $20.01, for a total value of $400,200.00. Following the sale, the general counsel owned 105,386 shares of the company’s stock, valued at $2,108,773.86. This trade represents a 15.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 179,964 shares of company stock worth $4,106,481. Corporate insiders own 7.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in CNTA. Bank of New York Mellon Corp purchased a new stake in shares of Centessa Pharmaceuticals during the first quarter valued at about $147,000. Cerity Partners LLC bought a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $471,000. Windmill Hill Asset Management Ltd purchased a new stake in Centessa Pharmaceuticals during the first quarter valued at approximately $1,696,000. XTX Topco Ltd boosted its stake in Centessa Pharmaceuticals by 81.0% in the first quarter. XTX Topco Ltd now owns 41,057 shares of the company’s stock valued at $590,000 after acquiring an additional 18,377 shares in the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Centessa Pharmaceuticals in the first quarter worth $3,273,000. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.